Clene Inc.
Clene Inc. (CLNN) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · CLNN · as of Jun 8, 2026
Key Statistics
Explore Clene Inc. Data
clnn stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 8 · Buy rate: 87.5%
The CLNN analyst consensus is Buy, based on ratings from 8 Wall Street analysts over the past 3 months. The average 12-month price target is $50.00, representing +831.19% upside from the current price of $5.37.
Competitors & Peers
clnn competitorsCLNN
CNTB
CNTX
COYA
MGNX
ORMPStock Performance
Full HistoryAbout Clene Inc.
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nan…
what is clene inc. · clnn stock overview · clene inc. company profile · who is clene inc. ceo · clnn NASDAQ · clene inc. headquarters · clene inc. business segments
About Stock Overview & Key Data
Clene Inc. (CLNN) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Oct 18, 2018. As of the latest trading session, CLNN stock price is $5.37, with a market capitalization of $55.3M. The stock has returned +27.13% over the past 12 months and -8.60% year-to-date.
According to 8 Wall Street analysts, the consensus rating for Clene Inc. stock is Buy, with an average 12-month price target of $50.00. In fiscal year 2025, Clene Inc. reported revenue of $200000.00 and net income of -$26.2M. For detailed data — including Clene Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Clene Inc. (CLNN) stock price is $5.37. The stock is traded on NASDAQ under the ticker symbol CLNN. The 52-week range is $3.25 – $13.50.